Quantrx Biomedical
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of h… Read more
Quantrx Biomedical (QTXB) - Total Liabilities
Latest total liabilities as of September 2022: $2.85 Million USD
Based on the latest financial reports, Quantrx Biomedical (QTXB) has total liabilities worth $2.85 Million USD as of September 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Quantrx Biomedical - Total Liabilities Trend (1994–2021)
This chart illustrates how Quantrx Biomedical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Quantrx Biomedical Competitors by Total Liabilities
The table below lists competitors of Quantrx Biomedical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Secure Trust Bank PLC
LSE:STB
|
UK | GBX3.91 Billion |
|
LINGBAO GOLD -H- (LI9.SG)
STU:LI9
|
Germany | €5.29 Billion |
|
Aquila SA
PA:ALAQU
|
France | €5.99 Million |
Liability Composition Analysis (1994–2021)
This chart breaks down Quantrx Biomedical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 528.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantrx Biomedical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantrx Biomedical (1994–2021)
The table below shows the annual total liabilities of Quantrx Biomedical from 1994 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-12-31 | $2.65 Million | +8.64% |
| 2020-12-31 | $2.44 Million | +7.54% |
| 2019-12-31 | $2.27 Million | +8.50% |
| 2018-12-31 | $2.09 Million | -2.44% |
| 2017-12-31 | $2.14 Million | +13.18% |
| 2016-12-31 | $1.89 Million | +5.61% |
| 2015-12-31 | $1.79 Million | +5.00% |
| 2014-12-31 | $1.71 Million | +56.78% |
| 2013-12-31 | $1.09 Million | +27.44% |
| 2012-12-31 | $853.57K | +89.20% |
| 2011-12-31 | $451.15K | -46.65% |
| 2010-12-31 | $845.57K | -38.07% |
| 2009-12-31 | $1.37 Million | -79.11% |
| 2008-12-31 | $6.54 Million | +260.76% |
| 2007-12-31 | $1.81 Million | +142.72% |
| 2006-12-31 | $746.46K | +179.35% |
| 2005-12-31 | $267.21K | -62.98% |
| 2004-12-31 | $721.87K | -35.68% |
| 2003-12-31 | $1.12 Million | +2.75% |
| 2002-12-31 | $1.09 Million | -13.99% |
| 2001-12-31 | $1.27 Million | +62.82% |
| 2000-12-31 | $780.00K | +8.33% |
| 1999-12-31 | $720.00K | -37.39% |
| 1998-12-31 | $1.15 Million | -7.26% |
| 1997-12-31 | $1.24 Million | +2.48% |
| 1996-12-31 | $1.21 Million | +332.14% |
| 1995-12-31 | $280.00K | -87.44% |
| 1994-12-31 | $2.23 Million | -- |